Matrix-regulated integrin αvβ5 maintains α5 β1 -dependent desmoplastic traits prognostic of neoplastic recurrence

eLife

Volumn 6, Issue , 2017, Pages

  Franco Barraza, Janusz ^a   Francescone, Ralph ^a   Luong, Tiffany ^a   Shah, Neelima ^a   Madhani, Raj ^a   Cukierman, Gil ^a   Dulaimi, Essel ^a   Devarajan, Karthik ^a   Egleston, Brian L ^a   Nicolas, Emmanuelle ^a   Alpaugh, R Katherine ^a   Malik, Ruchi ^a   Uzzo, Robert G ^a   Hoffman, John P ^a   Golemis, Erica A ^a   Cukierman, Edna ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 5 BETA 1 INTEGRIN; ALPHA5 INTEGRIN; BETA INTEGRIN; CYTOKERATIN; GLYCOPROTEIN; LENTIVIRUS VECTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VIMENTIN;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; BIOINFORMATICS; CANCER ASSOCIATED FIBROBLAST; CELL ACTIVATION; CELL ADHESION; CELL ISOLATION; CONTROLLED STUDY; CRISPR CAS SYSTEM; DESMOPLASIA; DIGITAL IMAGING; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; FIBROMA; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE INACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN MICROARRAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRESS FIBER; SURVIVAL; TUMOR RECURRENCE; WESTERN BLOTTING;

EID: 85011320535     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.20600.001     Document Type: Article

References (101)

1. Achterberg VF, Buscemi L, Diekmann H, Smith-Clerc J, Schwengler H, Meister JJ, Wenck H, Gallinat S, Hinz B. 2014. The nano-scale mechanical properties of the extracellular matrix regulate dermal fibroblast function. Journal of Investigative Dermatology 134:1862–1872. doi: 10.1038/jid.2014.90
2. Akiyama SK, Yamada SS, Chen WT, Yamada KM. 1989. Analysis of fibronectin receptor function with monoclonal antibodies: roles in cell adhesion, migration, matrix assembly, and cytoskeletal organization. The Journal of Cell Biology 109:863–875. doi: 10.1083/jcb.109.2.863
3. Alexander J, Cukierman E. 2016. Stromal dynamic reciprocity in cancer: intricacies of fibroblastic-ECM interactions. Current Opinion in Cell Biology 42:80–93. doi: 10.1016/j.ceb.2016.05.002
4. Amatangelo MD, Bassi DE, Klein-Szanto AJ, Cukierman E. 2005. Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. The American Journal of Pathology 167:475–488. doi: 10.1016/S0002-9440(10)62991-4
5. Anderson AR, Weaver AM, Cummings PT, Quaranta V. 2006. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 127:905–915. doi: 10.1016/j.cell.2006.09.042
6. Asano Y, Ihn H, Yamane K, Jinnin M, Tamaki K. 2006. Increased expression of integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. The American Journal of Pathology 168:499–510. doi: 10. 2353/ajpath.2006.041306
7. Bever KM, Sugar EA, Bigelow E, Sharma R, Laheru D, Wolfgang CL, Jaffee EM, Anders RA, De Jesus-Acosta A, Zheng L. 2015. The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. HPB 17:292–298. doi: 10.1111/hpb.12334
8. Bijlsma MF, van Laarhoven HW. 2015. The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal. Cancer and Metastasis Reviews 34:97–114. doi: 10.1007/s10555-014-9541-1
9. Binkley CE, Zhang L, Greenson JK, Giordano TJ, Kuick R, Misek D, Hanash S, Logsdon CD, Simeone DM. 2004. The molecular basis of pancreatic fibrosis: common stromal gene expression in chronic pancreatitis and pancreatic adenocarcinoma. Pancreas 29:254–263. doi: 10.1097/00006676-200411000-00003
10. Bissell MJ, Hines WC. 2011. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nature Medicine 17:320–329. doi: 10.1038/nm.2328
11. Bredfeldt JS, Liu Y, Conklin MW, Keely PJ, Mackie TR, Eliceiri KW. 2014. Automated quantification of aligned collagen for human breast carcinoma prognosis. Journal of Pathology Informatics 5:28. doi: 10.4103/2153-3539.139707
12. Callahan JF, Burgess JL, Fornwald JA, Gaster LM, Harling JD, Harrington FP, Heer J, Kwon C, Lehr R, Mathur A, Olson BA, Weinstock J, Laping NJ. 2002. Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). Journal of Medicinal Chemistry 45:999–1001. doi: 10.1021/ jm010493y
13. Caswell PT, Chan M, Lindsay AJ, McCaffrey MW, Boettiger D, Norman JC. 2008. Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. The Journal of Cell Biology 183:143–155. doi: 10.1083/jcb.200804140
14. Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, McConkey DJ. 2014. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nature Reviews Urology 11:400–410. doi: 10.1038/nrurol.2014. 129
15. Clark K, Pankov R, Travis MA, Askari JA, Mould AP, Craig SE, Newham P, Yamada KM, Humphries MJ. 2005. A specific alpha5beta1-integrin conformation promotes directional integrin translocation and fibronectin matrix formation. Journal of Cell Science 118:291–300. doi: 10.1242/jcs.01623
16. Conklin MW, Eickhoff JC, Riching KM, Pehlke CA, Eliceiri KW, Provenzano PP, Friedl A, Keely PJ. 2011. Aligned collagen is a prognostic signature for survival in human breast carcinoma. The American Journal of Pathology 178:1221–1232. doi: 10.1016/j.ajpath.2010.11.076
17. Counter CM, Hahn WC, Wei W, Caddle SD, Beijersbergen RL, Lansdorp PM, Sedivy JM, Weinberg RA. 1998. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. PNAS 95: 14723–14728. doi: 10.1073/pnas.95.25.14723
18. Cukierman E, Pankov R, Stevens DR, Yamada KM. 2001. Taking cell-matrix adhesions to the third dimension. Science 294:1708–1712. doi: 10.1126/science.1064829
19. Dekker TJ, Charehbili A, Smit VT, ten Dijke P, Kranenbarg EM, van de Velde CJ, Nortier JW, Tollenaar RA, Mesker WE, Kroep JR. 2015. Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial. Molecular Oncology 9:1120–1128. doi: 10.1016/j.molonc.2015.02.001
20. Desmoulière A, Geinoz A, Gabbiani F, Gabbiani G. 1993. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. The Journal of Cell Biology 122:103–111. doi: 10.1083/jcb.122.1.103
21. Dolberg DS, Bissell MJ. 1984. Inability of rous sarcoma virus to cause sarcomas in the avian embryo. Nature 309: 552–556. doi: 10.1038/309552a0
22. Dugina V, Fontao L, Chaponnier C, Vasiliev J, Gabbiani G. 2001. Focal adhesion features during myofibroblastic differentiation are controlled by intracellular and extracellular factors. Journal of Cell Science 114:3285–3296
23. Dvorak HF. 1986. Tumors: wounds that do not heal. similarities between tumor stroma generation and wound healing. The New England Journal of Medicine 315:1650–1659. doi: 10.1056/NEJM198612253152606
24. Erkan M, Kleeff J, Gorbachevski A, Reiser C, Mitkus T, Esposito I, Giese T, Büchler MW, Giese NA, Friess H. 2007. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 132:1447–1464. doi: 10.1053/j.gastro.2007.01.031
25. Erkan M, Michalski CW, Rieder S, Reiser-Erkan C, Abiatari I, Kolb A, Giese NA, Esposito I, Friess H, Kleeff J. 2008. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clinical Gastroenterology and Hepatology 6:1155–1161. doi: 10.1016/j.cgh.2008.05.006
26. Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, Geuze HJ. 1998. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. Journal of Biological Chemistry 273:20121–20127. doi: 10.1074/jbc.273.32.20121
27. Eyden B. 2001. The myofibroblast: an assessment of controversial issues and a definition useful in diagnosis and research. Ultrastructural Pathology 25:39–50. doi: 10.1080/019131201300004672
28. Fehlner-Gardiner CC, Uniyal S, von Ballestrem CG, Chan BM. 1996. Differential utilization of VLA-4 (alpha 4 beta 1) and -5 (alpha 5 beta 1) integrins during the development of mouse bone marrow-derived mast cells. Differentiation 60:317–325. doi: 10.1046/j.1432-0436.1996.6050317
29. Fogerty FJ, Akiyama SK, Yamada KM, Mosher DF. 1990. Inhibition of binding of fibronectin to matrix assembly sites by anti-integrin (alpha 5 beta 1) antibodies. The Journal of Cell Biology 111:699–708. doi: 10.1083/jcb. 111.2.699
30. Franco-Barraza J, Beacham DA, Amatangelo MD, Cukierman E. 2016. Preparation of extracellular matrices produced by cultured and primary fibroblasts. Current Protocols in Cell Biology 71:10.9.1–10.9.10. doi: 10.1002/cpcb.2
31. Froeling FE, Feig C, Chelala C, Dobson R, Mein CE, Tuveson DA, Clevers H, Hart IR, Kocher HM. 2011. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-b-catenin signaling to slow tumor progression. Gastroenterology 141:1486–1497. doi: 10.1053/j.gastro.2011.06.047
32. Garcia MN, Grasso D, Lopez-Millan MB, Hamidi T, Loncle C, Tomasini R, Lomberk G, Porteu F, Urrutia R, Iovanna JL. 2014. IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation. Journal of Clinical Investigation 124:4709–4722. doi: 10.1172/JCI76037
33. Goetz JG, Minguet S, Navarro-Lérida I, Lazcano JJ, Samaniego R, Calvo E, Tello M, Osteso-Ibáñez T, Pellinen T, Echarri A, Cerezo A, Klein-Szanto AJ, Garcia R, Keely PJ, Sánchez-Mateos P, Cukierman E, Del Pozo MA. 2011. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 146:148–163. doi: 10.1016/j.cell.2011.05.040
34. Goffin JM, Pittet P, Csucs G, Lussi JW, Meister JJ, Hinz B. 2006. Focal adhesion size controls tension-dependent recruitment of alpha-smooth muscle actin to stress fibers. The Journal of Cell Biology 172:259–268. doi: 10. 1083/jcb.200506179
35. Goreczny GJ, Ouderkirk-Pecone JL, Olson EC, Krendel M, Turner CE. 2016. Hic-5 remodeling of the stromal matrix promotes breast tumor progression. Oncogene. doi: 10.1038/onc.2016.422
36. Gupta V, Bassi DE, Simons JD, Devarajan K, Al-Saleem T, Uzzo RG, Cukierman E. 2011. Elevated expression of stromal palladin predicts poor clinical outcome in renal cell carcinoma. PLoS One 6:e21494. doi: 10.1371/ journal.pone.0021494
37. Handley DA, Arbeeny CM, Witte LD, Chien S. 1981. Colloidal gold–low density lipoprotein conjugates as membrane receptor probes. PNAS 78:368–371. doi: 10.1073/pnas.78.1.368
38. Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, Cleverly AL, Desaiah D, Guba SC, Benhadji KA, Slapak CA, Lahn MM. 2015. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Design, Development and Therapy 9:4479–4499. doi: 10.2147/DDDT.S86621
39. Hesler RA, Huang JJ, Starr MD, Treboschi VM, Bernanke AG, Nixon AB, McCall SJ, White RR, Blobe GC. 2016. TGF-b-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. Carcinogenesis 37:1041–1051. doi: 10.1093/carcin/bgw093
40. Hinz B, Dugina V, Ballestrem C, Wehrle-Haller B, Chaponnier C. 2003. Alpha-smooth muscle actin is crucial for focal adhesion maturation in myofibroblasts. Molecular Biology of the Cell 14:2508–2519. doi: 10.1091/mbc. E02-11-0729
41. Hinz B. 2016. Myofibroblasts. Experimental Eye Research 142:56–70. doi: 10.1016/j.exer.2015.07.009
42. Horton ER, Humphries JD, Stutchbury B, Jacquemet G, Ballestrem C, Barry ST, Humphries MJ. 2016. Modulation of FAK and Src adhesion signaling occurs independently of adhesion complex composition. The Journal of Cell Biology 212:349–364. doi: 10.1083/jcb.201508080
43. Ilić D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, Nomura S, Fujimoto J, Okada M, Yamamoto T. 1995. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377:539–544. doi: 10.1038/377539a0
44. Ireland L, Santos A, Ahmed MS, Rainer C, Nielsen SR, Quaranta V, Weyer-Czernilofsky U, Engle DD, Perez-Mancera PA, Coupland SE, Taktak A, Bogenrieder T, Tuveson DA, Campbell F, Schmid MC, Mielgo A. 2016. Chemoresistance in pancreatic cancer is driven by Stroma-Derived Insulin-Like growth factors. Cancer Research 76:6851–6863. doi: 10.1158/0008-5472.CAN-16-1201
45. Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK. 2012. State of the science: an update on renal cell carcinoma. Molecular Cancer Research 10:859–880. doi: 10.1158/1541-7786.MCR-12-0117
46. Kalluri R, Zeisberg M. 2006. Fibroblasts in cancer. Nature Reviews Cancer 6:392–401. doi: 10.1038/nrc1877
47. Khan Z, Marshall JF. 2016. The role of integrins in TGFb activation in the tumour stroma. Cell and Tissue Research 365:657–673. doi: 10.1007/s00441-016-2474-y
48. Klemm F, Joyce JA. 2015. Microenvironmental regulation of therapeutic response in cancer. Trends in Cell Biology 25:198–213. doi: 10.1016/j.tcb.2014.11.006
49. Klingberg F, Chow ML, Koehler A, Boo S, Buscemi L, Quinn TM, Costell M, Alman BA, Genot E, Hinz B. 2014. Prestress in the extracellular matrix sensitizes latent TGF-b1 for activation. The Journal of Cell Biology 207:283– 297. doi: 10.1083/jcb.201402006
50. Klinghoffer RA, Sachsenmaier C, Cooper JA, Soriano P. 1999. Src family kinases are required for integrin but not PDGFR signal transduction. The EMBO Journal 18:2459–2471. doi: 10.1093/emboj/18.9.2459
51. Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Bhosale PR, Tamm EP, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, et al. 2014. Transport properties of pancreatic cancer describe gemcitabine delivery and response. Journal of Clinical Investigation 124:1525–1536. doi: 10.1172/JCI73455
52. Laeseke PF, Chen R, Jeffrey RB, Brentnall TA, Willmann JK. 2015. Combining in vitro diagnostics with in vivo imaging for earlier detection of pancreatic ductal adenocarcinoma: Challenges and solutions. Radiology 277: 644–661. doi: 10.1148/radiol.2015141020
53. Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer DD, Mouw JK, LeBleu VS, Roy N, Novitskiy SV, Johansen JS, Poli V, Kalluri R, Iacobuzio-Donahue CA, Wood LD, Hebrok M, Hansen K, et al. 2016. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nature Medicine 22:497–505. doi: 10.1038/nm.4082
54. Langhans T. 1879. Pulsirende cavernoese geschwulst der miltz mit metastatischen knoten in der leber. Virchows Archiv 75:273–291. doi: 10.1007/bf02134657
55. Lee HO, Mullins SR, Franco-Barraza J, Valianou M, Cukierman E, Cheng JD. 2011. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 11:245. doi: 10.1186/1471-2407-11-245
56. Lim ST, Chen XL, Tomar A, Miller NL, Yoo J, Schlaepfer DD. 2010. Knock-in mutation reveals an essential role for focal adhesion kinase activity in blood vessel morphogenesis and cell motility-polarity but not cell proliferation. Journal of Biological Chemistry 285:21526–21536. doi: 10.1074/jbc.M110.129999
57. Lohi J, Leivo I, Oivula J, Lehto VP, Virtanen I. 1998. Extracellular matrix in renal cell carcinomas. Histology and Histopathology 13:785–796
58. Lygoe KA, Norman JT, Marshall JF, Lewis MP. 2004. AlphaV integrins play an important role in myofibroblast differentiation. Wound Repair and Regeneration 12:461–470. doi: 10.1111/j.1067-1927.2004.12402.x
59. Mana G, Clapero F, Panieri E, Panero V, Böttcher RT, Tseng HY, Saltarin F, Astanina E, Wolanska KI, Morgan MR, Humphries MJ, Santoro MM, Serini G, Valdembri D. 2016. PPFIA1 drives active a5b1 integrin recycling and controls fibronectin fibrillogenesis and vascular morphogenesis. Nature Communications 7:13546. doi: 10.1038/ ncomms13546
60. McDonald JA, Quade BJ, Broekelmann TJ, LaChance R, Forsman K, Hasegawa E, Akiyama S. 1987. Fibronectin’s cell-adhesive domain and an amino-terminal matrix assembly domain participate in its assembly into fibroblast pericellular matrix. The Journal of Biological Chemistry 262:2957–2967.
61. Meng XM, Nikolic-Paterson DJ, Lan HY. 2016. TGF-b: the master regulator of fibrosis. Nature Reviews Nephrology 12:325–338. doi: 10.1038/nrneph.2016.48
62. Mintz B, Illmensee K. 1975. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. PNAS 72:3585–3589. doi: 10.1073/pnas.72.9.3585
63. Mishra R, Zhu L, Eckert RL, Simonson MS. 2007. TGF-beta-regulated collagen type I accumulation: role of Src-based signals. American Journal of Physiology. Cell Physiology 292:C1361–C1369. doi: 10.1152/ajpcell.00370. 2006
64. Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung AH, Smyla JK, Anderson JM, Kim HJ, Bentrem DJ, Talamonti MS, Iacobuzio-Donahue CA, Hollingsworth MA, Yeh JJ. 2015. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nature Genetics 47:1168–1178. doi: 10.1038/ng.3398
65. Neuzillet C, Tijeras-Raballand A, Cohen R, Cros J, Faivre S, Raymond E, de Gramont A. 2015. Targeting the TGFb pathway for cancer therapy. Pharmacology & Therapeutics 147:22–31. doi: 10.1016/j.pharmthera.2014. 11.001
66. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, et al. 2009. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324:1457–1461. doi: 10.1126/science.1171362
67. Oshima H, Nakayama M, Han TS, Naoi K, Ju X, Maeda Y, Robine S, Tsuchiya K, Sato T, Sato H, Taketo MM, Oshima M. 2015. Suppressing TGFb signaling in regenerating epithelia in an inflammatory microenvironment is sufficient to cause invasive intestinal cancer. Cancer Research 75:766–776. doi: 10.1158/0008-5472.CAN-14-2036
68. Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, et al. 2014. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25:719–734. doi: 10.1016/j.ccr.2014.04.005
69. Paget S. 1889. The distribution of secondary growths in cancer of the breast. The Lancet 133:571–573. doi: 10. 1016/S0140-6736(00)49915-0
70. Pankov R, Cukierman E, Katz BZ, Matsumoto K, Lin DC, Lin S, Hahn C, Yamada KM. 2000. Integrin dynamics and matrix assembly: tensin-dependent translocation of alpha(5)beta(1) integrins promotes early fibronectin fibrillogenesis. The Journal of cell biology 148:1075–1090. doi: 10.1083/jcb.148.5.1075
71. Petersen OW, Rønnov-Jessen L, Howlett AR, Bissell MJ. 1992. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. PNAS 89:9064–9068. doi: 10.1073/pnas.89.19.9064
72. Principe DR, DeCant B, Diaz AM, Mangan RJ, Hwang R, Lowy A, Shetuni BB, Sreekumar BK, Chung C, Bentrem DJ, Munshi HG, Jung B, Grippo PJ, Bishehsari F. 2016. PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction. Oncotarget 7:28218–28234. doi: 10.18632/oncotarget.8587
73. Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ. 2006. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Medicine 4:38. doi: 10.1186/1741-7015-4-38
74. Reed NI, Jo H, Chen C, Tsujino K, Arnold TD, DeGrado WF, Sheppard D. 2015. The avb1 integrin plays a critical in vivo role in tissue fibrosis. Science Translational Medicine 7:288ra279. doi: 10.1126/scitranslmed.aaa5094
75. Rezakhaniha R, Agianniotis A, Schrauwen JT, Griffa A, Sage D, Bouten CV, van de Vosse FN, Unser M, Stergiopulos N. 2012. Experimental investigation of collagen waviness and orientation in the arterial adventitia using confocal laser scanning microscopy. Biomechanics and Modeling in Mechanobiology 11:461–473. doi: 10. 1007/s10237-011-0325-z
76. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, Fernandez-Zapico ME, Iacobuzio-Donahue C, Olive KP, Stanger BZ. 2014. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25:735–747. doi: 10.1016/j.ccr.2014.04.021
77. Roskelley CD, Bissell MJ. 1995. Dynamic reciprocity revisited: a continuous, bidirectional flow of information between cells and the extracellular matrix regulates mammary epithelial cell function. Biochemistry and Cell Biology 73:391–397. doi: 10.1139/o95-046
78. Rönty MJ, Leivonen SK, Hinz B, Rachlin A, Otey CA, Kähäri VM, Carpén OM. 2006. Isoform-specific regulation of the actin-organizing protein palladin during TGF-beta1-induced myofibroblast differentiation. Journal of Investigative Dermatology 126:2387–2396. doi: 10.1038/sj.jid.5700427
79. Ryan MC, Kostner H, Gordon KA, Duniho S, Sutherland MK, Yu C, Kim KM, Nesterova A, Anderson M, McEarchern JA, Law CL, Smith LM. 2010. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. British Journal of Cancer 103:676–684. doi: 10.1038/sj.bjc. 6605816
80. Sanjana NE, Shalem O, Zhang F. 2014. Improved vectors and genome-wide libraries for CRISPR screening. Nature Methods 11:783–784. doi: 10.1038/nmeth.3047
81. Sasson AR, Wetherington RW, Hoffman JP, Ross EA, Cooper H, Meropol NJ, Freedman G, Pingpank JF, Eisenberg BL. 2003. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. International Journal of Gastrointestinal Cancer 34:121–128. doi: 10.1385/IJGC: 34:2-3:121
82. Serini G, Bochaton-Piallat ML, Ropraz P, Geinoz A, Borsi L, Zardi L, Gabbiani G. 1998. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. The Journal of Cell Biology 142:873–881. doi: 10.1083/jcb.142.3.873
83. Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, Shimosegawa T, Apte MV, Wilson JS, Ng B, Lau SL, et al. 2014. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159:80–93. doi: 10.1016/j.cell.2014.08.007
84. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D. 1992. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359:693–699. doi: 10.1038/359693a0
85. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, Parsons JT. 2007. Cellular characterization of a novel focal adhesion kinase inhibitor. Journal of Biological Chemistry 282:14845–14852. doi: 10.1074/jbc.M606695200
86. Soto AM, Sonnenschein C. 2011. The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. BioEssays 33:332–340. doi: 10.1002/bies.201100025
87. Stromnes IM, DelGiorno KE, Greenberg PD, Hingorani SR. 2014. Stromal reengineering to treat pancreas cancer. Carcinogenesis 35:1451–1460. doi: 10.1093/carcin/bgu115
88. Su G, Hodnett M, Wu N, Atakilit A, Kosinski C, Godzich M, Huang XZ, Kim JK, Frank JA, Matthay MA, Sheppard D, Pittet JF. 2007. Integrin alphavbeta5 regulates lung vascular permeability and pulmonary endothelial barrier function. American Journal of Respiratory Cell and Molecular Biology 36:377–386. doi: 10.1165/rcmb.2006-0238OC
89. Tape CJ, Ling S, Dimitriadi M, McMahon KM, Worboys JD, Leong HS, Norrie IC, Miller CJ, Poulogiannis G, Lauffenburger DA, Jørgensen C. 2016. Oncogenic KRAS regulates tumor cell signaling via stromal reciprocation. Cell 165:910–920. doi: 10.1016/j.cell.2016.03.029
90. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. 1998. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 95:779–791. doi: 10.1016/S0092-8674(00)81701-8
91. Wall SJ, Werner E, Werb Z, DeClerck YA. 2005. Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by fibrillar collagen. Journal of Biological Chemistry 280:40187–40194. doi: 10.1074/jbc.M508226200
92. Wang L, Pedroja BS, Meyers EE, Garcia AL, Twining SS, Bernstein AM. 2012. Degradation of internalized avb5 integrin is controlled by uPAR bound uPA: effect on b1 integrin activity and a-SMA stress fiber assembly. PLoS One 7:e33915. doi: 10.1371/journal.pone.0033915
93. Webber JP, Spary LK, Mason MD, Tabi Z, Brewis IA, Clayton A. 2016. Prostate stromal cell proteomics analysis discriminates normal from tumour reactive stromal phenotypes. Oncotarget 7:20124–20139. doi: 10.18632/ oncotarget.7716
94. Whatcott CJ, Han H, Von Hoff DD. 2015. Orchestrating the tumor microenvironment to improve survival for patients with pancreatic cancer: Normalization, not Destruction. The Cancer Journal 21:299–306. doi: 10.1097/ PPO.0000000000000140
95. Whitcomb DC, Pogue-Geile K. 2002. Pancreatitis as a risk for pancreatic cancer. Gastroenterology Clinics of North America 31:663–678. doi: 10.1016/S0889-8553(02)00004-3
96. Wong YC, Cunha GR, Hayashi N. 1992. Effects of mesenchyme of the embryonic urogenital sinus and neonatal seminal vesicle on the cytodifferentiation of the Dunning tumor: ultrastructural study. Acta Anatomica 143:139– 150. doi: 10.1159/000147240
97. Wu L, Bernard-Trifilo JA, Lim Y, Lim ST, Mitra SK, Uryu S, Chen M, Pallen CJ, Cheung NK, Mikolon D, Mielgo A, Stupack DG, Schlaepfer DD. 2008. Distinct FAK-Src activation events promote alpha5beta1 and alpha4beta1 integrin-stimulated neuroblastoma cell motility. Oncogene 27:1439–1448. doi: 10.1038/sj.onc.1210770
98. Xu F, Liu C, Zhou D, Zhang L. 2016. TGF-b/SMAD Pathway and Its Regulation in Hepatic Fibrosis. Journal of Histochemistry & Cytochemistry 64:157–167. doi: 10.1369/0022155415627681
99. Xu R, Boudreau A, Bissell MJ. 2009. Tissue architecture and function: dynamic reciprocity via extra- and intracellular matrices. Cancer and Metastasis Reviews 28:167–176. doi: 10.1007/s10555-008-9178-z
100. Xu Y, Lu Y, Song J, Dong B, Kong W, Xue W, Zhang J, Huang Y. 2015. Cancer-associated fibroblasts promote renal cell carcinoma progression. Tumor Biology 36:3483–3488. doi: 10.1007/s13277-014-2984-8
101. Zoppi N, Barlati S, Colombi M. 2008. FAK-independent alphavbeta3 integrin-EGFR complexes rescue from anoikis matrix-defective fibroblasts. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1783:1177– 1188. doi: 10.1016/j.bbamcr.2008.03.003s